Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jubilant Therapeutics
Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026
September 15, 2026